Items tagged with Treatment
The Stop TB Partnership's Global Drug Facility Pediatric Drug-Resistant TB initiative (post)
The Stop TB Partnership’s Global Drug Facility officially launched the Pediatric Drug-Resistant TB (DR-TB) Initiative aimed at ending the disease by increasing the access of child-friendly DR-TB treatments to children who need them, wherever they are in the world.
Webinar: Advocacy for access to DR-TB treatment - webinar materials now available online (post)
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment. The webinar materials are now available online.
TB Alliance announces partnership with Hongqi Pharma to commercialize new therapy for highly drug-resistant forms of TB in China (post)
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.
Low BMI, presence of diabetes affect TB treatment outcomes (post)
Low BMI was significantly associated with an increased risk for adverse treatment outcomes in patients with tuberculosis, although comorbid diabetes resulted in “unexpectedly” better outcomes for these patients, according to a study in a South Indian cohort.
Unitaid invests in long-acting medicines to simplify treatment and prevention for HIV, TB, malaria and HCV (post)
Geneva, 30 January 2020 – Unitaid will invest US$ 39 million in two projects to speed up the development of long-acting versions of medicines for low- and middle-income countries. Innovative ways to administer drugs, which have revolutionized contraception and the treatment of schizophrenia, could redefine prevention and treatment of infectious diseases, but remain at early stages of research because of market barriers.
ERA4TB to accelerate the development of comprehensive treatments against TB (post)
With a team of more than thirty public and private organisations and a budget over 200 million euro, ERA4TB aims to radically transform the way in which new therapies are developed for the treatment of tuberculosis.
CGD experts discuss MVAC blueprint to create market for new TB drugs (post)
Center for Global Development (CGD): A Final MVAC Blueprint — and the Start of an R&D Revolution?
WHO FAQs on key changes to the treatment of drug-resistant TB (post)
The World Health Organization (WHO) Global TB Program, in close collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the United States Agency for International Development (USAID) and the Global Drug Facility of the Stop TB Partnership have updated the Frequently Asked Questions (FAQs) document on WHO’s Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis.
Stop TB Partnership’s Global Drug Facility Pediatric DR-TB Initiative short film (post)
The Stop TB Partnership’s Global Drug Facility (GDF) announced the submission of a short film about the Pediatric Drug-Resistant TB (DR-TB) Initiative into the Webby Awards.
The Union announces results for the shortened DR-TB treatment regimen (post)
Union Study shows long-term effectiveness for shortened DR-TB treatment regimen up to 24 months after treatment completion
Page 51 of 106 · Total posts: 0
←First 50 51 52 Last→